Clinical Trials Browser

Completed × OTHER × Brentuximab Vedotin × Clear all

NCT02588651 2025-11-21

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Phase 2 Completed

23 enrolled 15 charts

LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT02227199 2025-11-18

BV-ICE

Phase 1/2 Completed

45 enrolled 14 charts

Hodgkin Disease

NCT01508312 2025-10-21

Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Completed

66 enrolled 14 charts

Hodgkin Disease

NCT03496779 2025-07-30

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

Phase 2 Completed

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT03409432 2025-07-25

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Phase 2 Completed

DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT02616965 2025-04-04

A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

Phase 1 Completed

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT02388490 2024-09-23

Bretuximab

Phase 2 Completed

25 enrolled 12 charts

Lymphoma, Recurrence

NCT02191930 2024-08-23

BVB

Phase 2 Completed

Hodgkin Disease

NCT03217643 2024-06-20

EATL-001

Phase 2 Completed

Enteropathy-Associated T-Cell Lymphoma

NCT03013933 2024-02-22

Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1 Completed

Hodgkin Disease

NCT02398240 2023-10-26

Brentuximab for Newly Diagnosed Hodgkin Disease

Phase 2 Completed

Hodgkin Disease

NCT02292979 2022-08-19

BREACH

Phase 2 Completed

Hodgkin Disease

NCT03302728 2022-05-19

EpiBrentlen

Phase 1 Completed

DermatologicLymphoid

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT02429375 2022-05-12

Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1/2 Completed

7 enrolled 10 charts

Hodgkin Disease, Recurrence

NCT02086604 2022-02-17

Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 1 Completed

Lymphoma, Large B-Cell, Diffuse

NCT01578967 2021-12-07

Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

Phase NA Completed

41 enrolled 14 charts

Hodgkin Disease

NCT02686346 2021-12-07

BV-ICE

Phase 1/2 Completed

Hodgkin Disease, Recurrence

NCT02298283 2021-07-26

BRAPP2

Phase 2 Completed

Hodgkin Disease

NCT02227433 2020-12-22

FIL_BVHD01

Phase 2 Completed

Hodgkin Disease

NCT02505269 2020-08-24

Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma

Phase 2 Completed

34 enrolled 7 charts

Hodgkin Disease

NCT01657331 2020-07-17

SGN+Benda

Phase 1/2 Completed

Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic

NCT01830777 2020-04-14

Brentuximab Vedotin + Re-induction Chemotherapy for AML

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02822586 2019-08-30

TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome

Phase 1 Completed

Mycosis Fungoides, Sezary Syndrome

NCT02243436 2019-04-24

Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma

Phase 1/2 Completed

Hodgkin Disease, Lymphoma

NCT01700751 2019-04-16

Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation

Phase 1 Completed

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01807598 2019-01-29

Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia

Phase 2 Completed

10 enrolled 14 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT01569204 2018-10-29

Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma

Phase 2 Completed

Hodgkin Disease

NCT02280785 2018-09-06

BRAN

Phase 2 Completed

Lymphoma, Non-Hodgkin

NCT02567851 2018-05-11

BREVITY

Phase 2 Completed

Hodgkin Disease, Lymphoma

NCT01393717 2018-04-26

Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma

Phase 2 Completed

57 enrolled 14 charts

Hodgkin Disease

NCT01534078 2018-02-20

Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma

Phase 2 Completed

34 enrolled 15 charts

Hodgkin Disease

NCT02244021 2018-02-09

BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV

Phase 2 Completed

Hodgkin Disease

NCT01851200 2018-02-07

Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors

Phase 2 Completed

Neoplasm Metastasis, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Carcinoma, Embryonal

NCT01396070 2017-04-05

Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level

Phase 2 Completed

36 enrolled 13 charts

DermatologicLymphoid

Lymphoma, Non-Hodgkin, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous